ReviewInternational journal of molecular sciences2025
Biomarkers in Contrast-Induced Nephropathy: Advances in Early Detection, Risk Assessment, and Prevention Strategies.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nicorandil for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a meta-analysis.Future cardiology · 2025Pooled it
- Update on Contrast-Induced Nephropathy: Recent Developments in Its Prevention, Early Diagnosis, and Therapy.Medicina (Kaunas, Lithuania) · 2026Review
- The Role of Endothelial Activation and Stress Index (EASIX) for Predicting Contrast-Induced Nephropathy and In-Hospital Mortality in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.Diagnostics (Basel, Switzerland) · 2026Article
- Complete versus culprit only revascularization in young STEMI patients with multivessel disease.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2026Article
- Predictive Performance of the Aggregate Index of Systemic Inflammation for Contrast-Induced Nephropathy After PCI in Elderly ACS Patients.Medicina (Kaunas, Lithuania) · 2026Article
- Artificial Intelligence in Nephrology-State of the Art on Theoretical Background, Molecular Applications, and Clinical Interpretation.International journal of molecular sciences · 2026Review
- Machine Learning-Based Prediction and Feature Attribution Analysis of Contrast-Associated Acute Kidney Injury in Patients with Acute Myocardial Infarction.Medicina (Kaunas, Lithuania) · 2026Article
- Prognostic Value of Serum Cystatin C for Predicting Contrast-Induced Nephropathy in Elderly Individuals Aged Over 80 Years.Advances in urology · 2026Article
- Research progress on risk factors and early predictors of contrast-induced nephropathy.American journal of translational research · 2026Review
- Article
- Creatinine Decline Rate as a Predictor of Renal Recovery After Acute Kidney Injury: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2025Article
- Inflammatory Biomarkers Predicting Contrast-Induced Acute Kidney Injury in Elderly Patients with ST-Segment Elevation Myocardial Infarction.Diagnostics (Basel, Switzerland) · 2025Article
- The impact of short-term administration of dapagliflozin on contrast-induced acute kidney injury in patients with type 2 diabetes and renal insufficiency undergoing percutaneous coronary intervention.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Contrast-induced nephropathy (CIN) represents a significant complication associated with the use of iodinated contrast media (ICM), especially in individuals with preexisting renal impairment. The pathophysiology of CIN encompasses oxidative stress, inflammation, endothelial dysfunction, and hemodynamic disturbances, resulting in acute kidney injury (AKI). Early detection is essential for effective management; however, conventional markers like serum creatinine (sCr) and estimated glomerular filtration rate (eGFR) exhibit limitations in sensitivity and timeliness. This review emphasizes the increasing significance of novel biomarkers in enhancing early detection and risk stratification of contrast-induced nephropathy (CIN). Recent advancements in artificial intelligence and computational analytics have improved the predictive capabilities of these biomarkers, enabling personalized risk assessment and precision medicine strategies. Additionally, we discuss mitigation strategies, including hydration protocols, pharmacological interventions, and procedural modifications, aimed at reducing CIN incidence. Incorporating biomarker-driven assessments into clinical decision-making can enhance patient management and outcomes. Future research must prioritize the standardization of biomarker assays, the validation of predictive models across diverse patient populations, and the exploration of novel therapeutic targets. Utilizing advancements in biomarkers and risk mitigation strategies allows clinicians to improve the safety of contrast-enhanced imaging and reduce the likelihood of renal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.